BECTON DICKINSON & CO
Close on Oct 19, 2026
- Market cap
- $52.48B
- P/E (TTM)
- 57.6
- Dividend yield
- 2.18%
Earnings
Next report expected Oct 14, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $4.98B | $1.37 | $3.23 |
| Q2 FY2026 Ended Mar 31, 2026 | Apr 2, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 9, 2026 | Before market open | $5.25B | $1.34 | $2.91 |
| Q4 FY2025 Ended Sep 30, 2025 | Oct 15, 2025 | During market hours | $5.90B | – | – |
| Q3 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $5.30B | $1.07 | $3.35 |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 5, 2025 | During market hours | $5.20B | – | – |
| Q4 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $5.44B | $1.45 | $3.81 |
| Q3 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Dec 31, 2023 | Feb 1, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted Diluted EPSnon-GAAP | full year fiscal 2026 | $12.62 to $12.72 | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Becton Dickinson filed with the SEC
Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
Results of operations · EX-99.01 to Form 8-K
Mike Garrison to Retire from BD
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BD Appoints Vitor Roque Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
Results of operations · EX-99.01 to Form 8-K
Rick Byrd to Retire from BD
Executive or director change · Regulation FD disclosure · EX-99.01 to Form 8-K
Non-GAAP Financial Measures Included in the Financial Tables
Results of operations · EX-99.1 to Form 8-K
Becton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap and Aggregate Offer Cap
Other events · EX-99.1 to Form 8-K
Becton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for Purchase
Other events · EX-99.2 to Form 8-K
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
Other events · EX-99.1 to Form 8-K
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
Material agreement · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Investors: Shawn Bevec, SVP, Investor Relations - [email protected]
Results of operations · EX-99.1 to Form 8-K
New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD.
Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Adam Reiffe, VP, Investor Relations - 201-847-6927
Results of operations · EX-99.01 to Form 8-K
Investors: Adam Reiffe, VP, Investor Relations - 201-847-6927
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
Waters and BDs Biosciences & Diagnostic Solutions Business to Combine,
Regulation FD disclosure · EX-99.1 to Form 8-K
Science Tools & Diagnostics Leader Focused on Regulated, High-Volume Testing July 14, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Accelerating the New BD Strategy July
Regulation FD disclosure · EX-99.3 to Form 8-K
IN RE BECTON, DICKINSON AND COMPANY STOCKHOLDER DERIVATIVE LITIGATION
Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
BD Names Pamela Spikner as Chief Accounting Officer and Controller
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
BD to Acquire Edwards Lifesciences' Critical Care Product Group
Regulation FD disclosure · EX-99.1 to Form 8-K
BD RESTRICTED BD to Acquire Edwards Lifesciences Critical Care Product Group June 3, 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
Dave Hickey Announces Intent to Retire from BD
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Results of operations · EX-99.1 to Form 8-K
Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Results of operations · EX-99.1 to Form 8-K
Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Results of operations · EX-99.1 to Form 8-K
Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Results of operations · EX-99.1 to Form 8-K
Michelle Quinn Named Acting General Counsel for BD
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Investors: Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Becton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap
Other events · EX-99.1 to Form 8-K
Becton, Dickinson and Company Announces Pricing of the Tender Offers
Other events · EX-99.2 to Form 8-K